Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on Atossa Therapeutics’ strategic advancements in the development of Z-endoxifen for breast cancer risk reduction. The company has requested a Type C meeting with the FDA to explore an accelerated regulatory pathway, which could potentially shorten the approval process and reduce trial costs. This proactive approach aims to streamline the drug’s path to market by addressing complex regulatory questions early on.
Moreover, Z-endoxifen presents significant market potential due to its advantages over existing therapies like tamoxifen. It offers equivalent anti-estrogen activity with fewer adverse events and a pharmacokinetic profile that avoids the CYP2D6 metabolic pathway, ensuring more consistent drug levels. These factors, combined with the drug’s faster onset of action, position Z-endoxifen as a promising option to meet the high unmet needs in breast cancer treatment, thus supporting the Buy rating.